| Endometriosis

Lupron Depot vs Orilissa

Side-by-side clinical, coverage, and cost comparison for endometriosis.

Deep comparison between: Lupron Depot vs Orilissa with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsOrilissa has a higher rate of injection site reactions vs Lupron Depot based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Orilissa but not Lupron Depot, including UnitedHealthcare

Category

Lupron Depot

Orilissa

At A Glance

RouteIM injection

FrequencyEvery 3 months

ClassGnRH agonist

RouteOral

FrequencyOnce or twice daily

ClassGnRH receptor antagonist

Indications

Endometriosis
Uterine Fibroids

Endometriosis

Dosing

Endometriosis 11.25 mg IM every 3 months for 1 to 2 doses (up to 6 months); may be administered alone or with norethindrone acetate 5 mg daily add-back. Retreatment for up to 6 additional months requires norethindrone acetate add-back; total treatment duration must not exceed 12 months.

Uterine Fibroids One IM injection of 11.25 mg providing a single 3-month treatment course.

Endometriosis 150 mg once daily for up to 24 months, taken orally at approximately the same time each day with or without food.

Endometriosis with dyspareunia Consider 200 mg twice daily for up to 6 months, taken orally.

Endometriosis with moderate hepatic impairment (Child-Pugh Class B) 150 mg once daily for up to 6 months; 200 mg twice daily is not recommended.

Contraindications

Hypersensitivity to GnRH, GnRH agonist analogs including leuprolide acetate, or any excipient in LUPRON DEPOT 11.25 mg
Undiagnosed abnormal uterine bleeding
Pregnancy
When norethindrone acetate is co-administered, contraindications to norethindrone acetate also apply

Pregnancy (exposure early in pregnancy may increase risk of early pregnancy loss)
Known osteoporosis (risk of further bone loss)
Severe hepatic impairment (Child-Pugh C)
Concomitant use of OATP1B1 inhibitors known or expected to significantly increase elagolix plasma concentrations
Known hypersensitivity reaction to elagolix or any inactive component (including anaphylaxis and angioedema)

Drug Interactions

1147View drug interactions

1025View drug interactions

Adverse Reactions

Most common (>=5%) Hot flashes/sweats, headache, vaginitis, depression/emotional lability, general pain, weight gain/loss, nausea/vomiting, decreased libido, dizziness, acne, skin reactions

Serious Urinary tract infection, renal calculus, depression

Postmarketing Rash, urticaria, anaphylaxis, mood swings, depression, suicidal ideation, convulsion, peripheral neuropathy, serious liver injury, injection site reactions including induration/abscess/necrosis, spinal fracture, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, pituitary apoplexy

Most common (>=5%) Hot flush, headache, nausea, insomnia, mood altered/mood swings, amenorrhea, depressed mood/depression, anxiety, arthralgia

Serious Bone loss, change in menstrual bleeding pattern, suicidal ideation and suicidal behavior, exacerbation of mood disorders, hepatic transaminase elevations

Postmarketing Hypersensitivity reactions including anaphylaxis, angioedema, and urticaria

Pharmacology

Long-acting GnRH agonist that causes initial stimulation followed by prolonged suppression of pituitary gonadotropins, resulting in decreased gonadal steroid secretion and quiescence of estrogen-dependent tissues; effect is reversible upon discontinuation.

GnRH receptor antagonist; elagolix competitively binds GnRH receptors in the pituitary gland, causing dose-dependent suppression of LH and FSH and reducing ovarian estradiol and progesterone concentrations.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Lupron Depot